"HEALTH ECONOMICS DEVELOPMENT PLAN" EARLY IN DEVELOPMENT PROCESS RECOMMENDED BY PAREXEL EXEC; GLOBAL QoL SCALES NOT SUFFICIENT FOR CLAIMS -- FDAer MORRIS
Executive Summary
Drug companies should construct a "complete health economics development plan" as early as possible in the drug development process, Parexel/S&FA Senior VP Peter Malamis advised at an Institute for International Research meeting May 19 in Washington, D.C.